These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35891435)

  • 1. Comparison of the Hemagglutination Inhibition Titers against Influenza Vaccine Strains in Japan from the 2017/2018 to 2021/2022 Seasons Using a Single Set of Serum Samples.
    Otani N; Nakajima K; Ishikawa K; Ichiki K; Yoda Y; Ueda T; Takesue Y; Yamamoto T; Tanimura S; Shima M; Okuno T
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.
    Kishida N; Fujisaki S; Yokoyama M; Sato H; Saito R; Ikematsu H; Xu H; Takashita E; Tashiro M; Takao S; Yano T; Suga T; Kawakami C; Yamamoto M; Kajiyama K; Saito H; Shimada S; Watanabe S; Aoki S; Taira K; Kon M; Lin JH; Odagiri T
    Clin Vaccine Immunol; 2012 Jun; 19(6):897-908. PubMed ID: 22492743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.
    Moehling KK; Zimmerman RK; Nowalk MP; Jeng Lin C; Martin JM; Alcorn JF; Susick M; Burroughs A; Holiday C; Flannery B; Levine MZ
    Vaccine; 2020 Jul; 38(33):5171-5177. PubMed ID: 32580919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
    McLean HQ; Levine MZ; King JP; Flannery B; Belongia EA
    Vaccine; 2021 Dec; 39(49):7146-7152. PubMed ID: 34774360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016.
    McLean HQ; King JP; Talley P; Flannery B; Spencer S; Levine MZ; Friedrich TC; Belongia EA
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):173-180. PubMed ID: 30759228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
    Niang M; Deming ME; Goudiaby D; Diop OM; Dia N; Diallo A; Ortiz JR; Diop D; Lewis KDC; Lafond KE; Widdowson MA; Victor JC; Neuzil KM
    Vaccine; 2020 Nov; 38(47):7526-7532. PubMed ID: 33012603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season.
    Gouma S; Zost SJ; Parkhouse K; Branche A; Topham DJ; Cobey S; Hensley SE
    Clin Infect Dis; 2020 Sep; 71(6):1447-1453. PubMed ID: 31598646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
    Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to influenza vaccination in nursing home residents and healthcare workers during four successive seasons in Niigata, Japan.
    Sato M; Saito R; Tanabe N; Nishikawa M; Sasaki A; Gejyo F; Suzuki H
    Infect Control Hosp Epidemiol; 2005 Nov; 26(11):859-66. PubMed ID: 16323321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays.
    Heeringa M; Leav B; Smolenov I; Palladino G; Isakov L; Matassa V
    J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32493784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of antibody response to 2019-20 cell-based inactivated and egg-based live attenuated influenza vaccines in children and young adults.
    Williams KV; Zhai B; Alcorn JF; Patricia Nowalk M; Levine MZ; Kim SS; Flannery B; Moehling Geffel K; Jaber Merranko A; Nagg JP; Collins M; Susick M; Clarke KS; Zimmerman RK; Martin JM
    Vaccine; 2022 Jan; 40(5):780-788. PubMed ID: 34952751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influenza surveillance in five consecutive seasons during post pandemic period: results from National Influenza Center, Turkey].
    Altaş AB; Bayrakdar F; Korukluoğlu G
    Mikrobiyol Bul; 2016 Jul; 50(3):401-17. PubMed ID: 27525396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of sample collection tube method, anticoagulant-containing plasma versus serum, on influenza virus hemagglutination inhibition titer and microneutralization titer serological assays.
    Morrison BJ; Martin NJ; Rehman T; Ewing D; Dewar RL; Metcalf J; Sun P; Beigel J; Luke TC; Raviprakash K
    BMC Health Serv Res; 2018 Aug; 18(1):651. PubMed ID: 30134892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.